Shingo Matsumoto

Nov 2, 2024 | jacc.org | Shingo Matsumoto |Pardeep S. Jhund |Alasdair Henderson |Johann Bauersachs

IntroductionKidney dysfunction often leads to reluctance to continue disease-modifying therapies in patients with heart failure (HF).

Aug 31, 2024 | onlinelibrary.wiley.com | Shingo Matsumoto |Alasdair Henderson |Li Shen |Toru Kondo

Supporting Information Filename Description ejhf3383-sup-0001-Supinfo.docxWord 2007 document , 5.9 MB Data S1. Supporting Information. References 1, , , , , , et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.

May 12, 2024 | jacc.org | Shingo Matsumoto |Alasdair Henderson |Li Shen |Mingming Yang

IntroductionRenal impairment is common in heart failure (HF) and kidney function often declines as the severity of HF progresses over time.1-4 To complicate this picture, several treatments for HF that improve outcomes can, paradoxically, lead to a decrease in the estimated glomerular filtration rate (eGFR).5,6 Because of this, there is a growing awareness that a modest initial decline in eGFR after starting these therapies may be acceptable.

Apr 8, 2024 | onlinelibrary.wiley.com | Shingo Matsumoto |Mingming Yang |Li Shen |Alasdair Henderson

Supporting Information Filename Description ejhf3223-sup-0001-FigureS1.docxWord 2007 document , 505.1 KB Appendix S1. Supporting Information. References 1, , , , . Polypharmacy definition and prevalence in heart failure: A systematic review. Heart Fail Rev 2022; 27: 465–492. https://doi.org/10.1007/s10741-021-10135-4 2, , , . What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17: 230. https://doi.org/10.1186/s12877-017-0621-2 3, , , , , , et al.

Sep 28, 2023 | onlinelibrary.wiley.com | Shingo Matsumoto |Toru Kondo |Mingming Yang |Ross Campbell

Supporting Information Filename Description ejhf3044-sup-0001-Supinfo.docxWord 2007 document , 1.6 MB Appendix S1. Supporting Information. References 1, , . Treatment of hypertension: A review. JAMA 2022; 328: 1849–1861. https://doi.org/10.1001/jama.2022.19590 2, , , , , , et al.; CLARIFY Investigators. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: An international cohort study. Eur Heart J 2019; 40: 1399–1407.